Print

DEVELOPMENT PROGRAMS

Decapeptyl®

The Group is participating in three phase III studies performed under the auspices of the International Breast Cancer Study Group for the treatment of pre-menopausal breast cancer, comparing traditional treatment methods with hormone therapy by combining Decapeptyl® with oestrogen suppressants such as Aromasin®, marketed by Pfizer. These studies are scheduled to run until 2015. Their findings could lead to a review of treatment guidelines for pre-menopausal women with hormone receptor expressing breast cancer.

The Group has obtained an exclusive know-how licence and new patent applications relating to worldwide marketing rights for Decapeptyl ® (triptorelin pamoate), excluding North America and some other countries such as Sweden, Israel, Iran and Japan. The Group thus has access to future sustained-release formulations of Decapeptyl® developed by Debiopharm, among which a 6-month sustained-release formulation launched in France in 2010.